Mineralys Therapeutics (MLYS) Stock Price, News & Analysis

Company Overview

Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing treatments for hypertension and other cardiovascular and kidney conditions associated with excess aldosterone. The company is based in Radnor, Pennsylvania, and was founded in 2019.

Its lead product candidate, lorundrostat, is an investigational oral inhibitor of aldosterone synthase. Mineralys is studying the drug as a potential treatment for difficult-to-control hypertension and conditions related to excess aldosterone; it is not an approved or marketed therapy.

The company’s work is focused on drug development and clinical research, with trials primarily conducted in the United States. Jon Congleton serves as Mineralys Therapeutics’ chief executive officer.

Key Stats

• Today's Range: $15.18 to $16.88
• 50-Day Range: $15.24 to $31.12
• 52-Week Range: $14.91 to $47.00
• Volume: 2.93 million shs
• Average Volume: 1.91 million shs
• Market Capitalization: $1.37 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $43.60
• Consensus Rating: Hold

Mineralys Therapeutics Stock Analysis - MarketRank™

Mineralys Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 360th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Hold

Consensus Rating

Mineralys Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on no strong buy ratings, 4 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Mineralys Therapeutics has a consensus price target of $43.60, representing about 181.3% upside from its current price of $15.50.

Amount of Analyst Coverage

Mineralys Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Mineralys Therapeutics are expected to grow in the coming year, from ($4.64) to ($2.35) per share.

Price to Book Value per Share Ratio

Mineralys Therapeutics has a P/B Ratio of 2.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.71% of the float of Mineralys Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Mineralys Therapeutics has a short interest ratio ("days to cover") of 4.95.

Change versus previous month

Short interest in Mineralys Therapeutics has recently increased by 3.35%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mineralys Therapeutics does not currently pay a dividend.

Dividend Growth

Mineralys Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.17

News Sentiment

Mineralys Therapeutics has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for Mineralys Therapeutics this week, compared to 5 articles on an average week.

Search Interest

2 people have searched for MLYS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

2 people have added Mineralys Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Mineralys Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,403,069.00 in company stock.

Percentage Held by Insiders

18.94% of the stock of Mineralys Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

84.46% of the stock of Mineralys Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/04/2026
• Today: 11/13/2026
• 9th Annual Evercore ISI HealthCONx Conference: 12/01/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:MLYS
• CIK: 1933414
• Web: www.mineralystx.com
• Phone: 888-378-6240
• Fax: N/A
• Employees: 76
• Year Founded: 2019

Price Target and Rating

• Average Price Target for Mineralys Therapeutics: $43.60
• High Price Target: $56.00
• Low Price Target: $29.00
• Potential Upside/Downside: +181.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.38
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.36)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$154.65 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -63.26%
• Return on Assets: -56.64%

Debt

• Debt-to-Equity Ratio: 0.15
• Current Ratio: 11.83
• Quick Ratio: 11.83

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.69 per share
• Price / Book: 2.72

Miscellaneous

• Outstanding Shares: 88,560,000
• Free Float: 71,784,000
• Market Cap: $1.37 billion
• Optionable: Optionable
• Beta: 0.83